Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Clearmind Medicine Inc
(NQ:
CMND
)
1.410
+0.010 (+0.71%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
73,485
Open
1.430
Bid (Size)
1.380 (25)
Ask (Size)
1.450 (1)
Prev. Close
1.400
Today's Range
1.380 - 1.450
52wk Range
0.9205 - 6.800
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why Aehr Test Systems Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
October 11, 2024
Via
Benzinga
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
October 10, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Performance
YTD
-49.28%
-49.28%
1 Month
+6.02%
+6.02%
3 Month
+10.16%
+10.16%
6 Month
-4.73%
-4.73%
1 Year
-66.90%
-66.90%
More News
Read More
Clearmind Medicine Files International Patent For Ibogaine Combination Therapy
September 17, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
September 16, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
September 12, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
September 06, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
September 06, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
August 29, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Could Psychedelics End Binge Drinking? A Breakthrough Patent Says Yes
August 23, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment
August 21, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
August 16, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
August 09, 2024
Via
InvestorPlace
Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
August 09, 2024
Via
Benzinga
Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug
August 06, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
August 06, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research
July 31, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
July 19, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Nasdaq Edges Lower; Morgan Stanley Earnings Top Views
July 16, 2024
Via
Benzinga
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 16, 2024
Via
Benzinga
Crude Oil Down 1%; Bank of America Posts Upbeat Earnings
July 16, 2024
Via
Benzinga
Exposures
Fossil Fuels
Why Is SciSparc (SPRC) Stock Up 25% Today?
July 16, 2024
Via
InvestorPlace
Topics
Intellectual Property
Exposures
Intellectual Property
Dow Jumps 400 Points; US Retail Sales Flat For June
July 16, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
July 16, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss
July 16, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
July 16, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
